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  Mutation in CALCRL abrogates RAMP interaction and causes autosomal 1 
recessive non-immune hydrops fetalis with lymphatic dysplasia 2 
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Running Title: hCALCRL Mutation Causes NIHF 34 
Summary: Using genetic, pharmacological and animal model approaches, we elucidate a novel 35 
human mutation in a G protein coupled receptor that impairs receptor oligomerization and 36 
trafficking leading to fatal, non-immune hydrops fetalis associated with arrested lymphatic 37 
development. 38 
       39 
Abstract:  40 
We report the first case of non-immune hydrops fetalis (NIHF) associated with a recessive, 41 
in frame deletion of residue V205 in the G protein-coupled receptor, Calcitonin Receptor Like 42 
Receptor (hCALCRL).  Homozygosity for hCALCRL(V205del) results in fetal demise from 43 
hydrops fetalis, while heterozygosity in female carriers is associated with spontaneous miscarriage 44 
and subfertility.  Using molecular dynamic modeling and sophisticated in vitro biochemical assays, 45 
we show that the receptor hCLR(V205del) mutant results in misfolding of the first extracellular 46 
loop of the receptor, precluding its association with its requisite receptor chaperone, receptor 47 
activity modifying protein (RAMP), and failure to translocate to the plasma membrane and signal.  48 
Furthermore, utilizing 3 independent genetic mouse models we establish that the adrenomedullin-49 
CLR-RAMP2 axis is both necessary and sufficient for driving lymphatic vascular proliferation 50 
during development.   Genetic ablation of either lymphatic endothelial Calcrl or non-endothelial 51 
Ramp2 in mice leads to severe NIHF with embryonic demise and placental pathologies, similar to 52 
that observed in humans.  Taken together, our results highlight a novel candidate gene for human 53 
congenital NIHF and provide structure-function insights into the importance of GPCR-RAMP 54 
interaction for human physiology. 55 
  56 
Introduction:  57 
In early stages of intrauterine development, changes in fluid distribution and equilibrium 58 
are not well tolerated (Brace, 1989; Brace and Valenzuela, 1990). Impaired lymphatic drainage in 59 
adults often presents with chronic swelling or lymphedema, but in the fetus it can develop into a 60 
more severe and lethal condition known as hydrops fetalis (HF) (Apkon, 1995; Bukowski and 61 
Saade, 2000; Randenberg, 2010a; Randenberg, 2010b). The term HF refers to excessive fluid 62 
accumulation within the fetal extra vascular compartments and body cavities and is characterized 63 
by generalized skin thickness of >5 mm, placental enlargement and edema, pericardial or pleural 64 
effusion, or ascites (Bellini et al., 2015; Bellini and Hennekam, 2012; Bellini et al., 2009). HF is 65 
further subdivided into two categories, Rhesus iso-immunization or immune hydrops fetalis and 66 
non-immune hydrops fetalis (NIHF). Effective Rhesus (Rh) alloimmunization during pregnancy 67 
has reduced the number immune related HF cases to <10% such that NIHF now accounts for 85-68 
90% of all hydrops cases. The etiology of NIHF is further subdivided into 14 classification groups 69 
based on the cause of the disorder (Randenberg, 2010a; Randenberg, 2010b). Within these 70 
subgroups, Generalized Lymphatic Dysplasia (GLD) is the third leading cause of NIHF, following 71 
cardiovascular and idiopathic disorders, the latter of which account for 20% of all known NIHF 72 
cases. 73 
In an attempt to understand the underlying causes of NIHF, Connell et al. developed a new 74 
classification system as a clinical and research tool to further delineate primary lymphedema 75 
conditions and facilitate the identification of new causative genes linked to GLD (Connell et al., 76 
2013).  Hennekam Syndrome (OMIM#235510) was the first inherited form of GLD described, and 77 
is caused by loss-of-function mutations in the collagen and calcium binding EGF domains 1 78 
(CCBE1) gene in an autosomal recessive manner (Alders et al., 2009; Connell et al., 2010).  More 79 
recently, biallelic mutations in piezo-type mechanosensitive ion channel component 1 (PIEZO1) 80 
and heterozygous inactivating mutations in the Eph receptor B4 (EPHB4) have also been identified 81 
as causative of GLD in humans (Fotiou et al., 2015; Lukacs et al., 2015; Martin-Almedina et al., 82 
2016). These new discoveries suggest that GLD is genetically heterogeneous and provides 83 
precedent for the identification of novel genetic pathways.   84 
Calcitonin receptor-like receptor (CALCRL, gene; CLR, protein) is a G protein-coupled 85 
receptor (GPCR) that forms an active signaling complex for either adrenomedullin (AM) peptide 86 
or calcitonin gene related peptide (CGRP), depending on the receptor’s interaction with a family 87 
of receptor activity-modifying proteins (RAMPs1-3) (Hay et al., 2006; Kamitani et al., 1999; 88 
McLatchie et al., 1998; Woolley and Conner, 2013).  Co-expression and direct protein-protein 89 
interaction of a RAMP with CLR is required for their forward translocation from the cytoplasm to 90 
the plasma membrane.  Moreover, the RAMP moiety also determines ligand binding specificity, 91 
such that an interaction between CLR and RAMP2 or RAMP3 leads to the formation of a receptor 92 
complex that preferentially binds AM (AM1 and AM2 receptors, respectively), while a CLR-93 
RAMP1 complex creates the active form of the CGRP-binding receptor.  Selective antagonists and 94 
neutralizing antibodies that exploit this unique paradigm of GPCR selectivity and function have 95 
very recently shown great promise in phase-III clinical trials for the therapeutic treatment of 96 
migraine (Goadsby et al., 2017; Silberstein et al., 2017). Yet, there are currently no known 97 
conditions or diseases associated with loss-of-function of these genes and signaling pathways in 98 
humans.  99 
We and others have used genetic approaches in mice to elucidate the developmental and 100 
physiological functions of this complex GPCR signaling pathway in vivo (Dackor et al., 2006; 101 
Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008; Kadmiel et al., 2011; Kamitani et al., 1999; 102 
Koyama et al., 2013). Although genetic loss of murine Ramp1, Ramp3 or CalcA/Bis compatible 103 
with long-term survival (Dackor et al., 2007), global deletion of the genes encoding either AM, 104 
CLR or RAMP2 results in embryonic lethality at mid-gestation characterized by marked hydrops 105 
fetalis caused by a developmental arrest of lymphangiogenesis (Caron and Smithies, 2001; Dackor 106 
et al., 2007; Dackor et al., 2006; Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008).  Additionally, 107 
female mice that are haploinsufficient for either Adm, Calcrl or Ramp2 exhibit significant 108 
subfertility associated with abnormal uterine receptivity, placental defects and fetal growth 109 
restriction, which are maternally-linked phenotypes largely independent of the genotype of the 110 
fetus (Li et al., 2008; Li et al., 2006). 111 
Here, we identify a novel recessive form of GLD that presents with NIHF and fetal demise 112 
in the homozygous state, as well as accompanying clinical subfertility in women heterozygous for 113 
a loss-of-function mutation in the CALCRL gene.  Utilizing molecular dynamic modeling, newly-114 
developed biochemistry approaches and in vivo conditional genetic models we further reveal that 115 
this in-frame deletion variant precludes the translocation of the active CLR-RAMP receptor 116 
complex to the plasma membrane, resulting in loss-of-function that, in complementary genetic 117 
mouse models, underscores the cell autonomous requirement of the CLR-RAMP2-AM signaling 118 
axis within lymphatic endothelial cells.   119 
 120 
Results:  121 
Clinical assessment of a family presenting with subfertility and hydropic fetuses 122 
 The proband, a twenty-two year old asymptomatic woman G4 P1211 (Figure 1A, III.4), with 123 
normal liver enzymes and no signs of diabetes mellitus or hypertension, was referred to the 124 
genetics clinic after experiencing 3 pregnancies resulting in intrauterine fetal demise. Her first 125 
pregnancy resulted in a healthy baby girl (IV.1). The second pregnancy (Figure 1A, IV.2) was 126 
complicated by hydrops fetalis (HF) and mild polyhydramnios, which were noticed during second 127 
trimester ultrasounds. The first ultrasound during the 22nd week of gestation was inconclusive due 128 
to fetal positioning.  However, the second ultrasound during the 27th week of gestation (26w+3d), 129 
which exhibited normal radiological parameters, confirmed the presence of HF, with a biparietal 130 
diameter measurement equivalent to 40w+5d and a head circumference equivalent to 33w+6d.  131 
Consistent with the diagnostic criteria for HF (Apkon, 1995; Bellini and Hennekam, 2012; Bellini 132 
et al., 2006; Bellini et al., 2009), significant interstitial fluid was noted in more than 2 extravascular 133 
compartments, including marked pleural effusion indicated by reduced lung size, marked skin 134 
edema and pericardial effusion.  The pericardial effusion was also associated with impaired cardiac 135 
outflow.  The pregnancy continued to 29 weeks, after which the fetal movement completely 136 
ceased.  137 
During the proband’s 3rd pregnancy (Figure 1A, IV.3), 2 ultrasounds were performed in 138 
the clinic. The first was at 12 weeks of gestation and was determined to be normal.  The second 139 
was at 21 weeks and showed normal cardiac outflow with no major anomalies.  However, at 22 140 
weeks of gestation, the proband noted poor intrauterine movements and an ultrasound revealed 141 
mild polyhydramnios with significant presentation of HF.  Due to the previous history of 142 
intrauterine fetal demise, blood was collected from the fetus for genetic testing. 143 
The proband’s 4th pregnancy (Figure 1A, IV.4) resulted in spontaneous miscarriage at 8 144 
weeks of gestation when she presented with sudden onset of vaginal bleeding.  No fetal or placental 145 
tissue was obtained from IV.4. 146 
 147 
Placental pathology consistent with hydrops fetalis 148 
Placental pathology was performed on IV.2 and IV.3 with findings consistent with the 149 
clinical presentation of HF. The umbilical cord of IV.2 appeared normal, with a trivascular 150 
structure consisting of 2 arteries and 1 vein.  In addition, the fetal membranes were translucent and 151 
negative for acute chorioamnionitis.  However, the singleton aborted placenta was edematous and 152 
large for the gestational age, weighing 1,113 g.  Compared to an unaffected, gestationally-matched, 153 
24-week placenta (Figure 1B, top panels), the placenta of IV.2 showed diffuse edematous 154 
chorionic villi, with severe villus edema and scattered Hofbauer cells (Figure 1B, middle panels).  155 
Furthermore, the fetal vessels appeared abnormally shaped and compressed, likely due to the 156 
encroaching villus edema. 157 
Similar to IV.2, the IV.3 singleton placenta was large for gestation age, weighing 484 g.  158 
The umbilical cord was trivascular with no noticeable acute arteritis or phlebitis.  The placenta 159 
was negative for villitis and viral cytopathic effects, with translucent membranes negative for acute 160 
chorioamnionitis.   However, histopathological evaluation revealed edematous chorionic villi, an 161 
increased number of Hofbaeur cells and chorangiosis (Figure 1B, bottom panels).  Once again, 162 
some of the fetal vessels appeared multi-lobular in shape and compressed to the outer rims of the 163 
chorionic villi, likely due to encroaching villus edema.  Taken together, these placental findings 164 
are consistent with the fetal presentation of NIHF. 165 
 166 
Exome Sequencing to identify causal CALCRL (V205del) variant 167 
The family history of consanguinity (Figure 1A) indicated that the fetal demise and 168 
resulting subfertility could be related to a homozygous variant. To address this hypothesis, exome 169 
sequencing was performed on blood samples collected from III.4, IV.1 and IV.3.  We first searched 170 
for potentially damaging variants in known genes recently implicated with NIHF with GLD, 171 
including PIEZO1 (Fotiou et al., 2015) and EPHB4 (Martin-Almedina et al., 2016), as well as 172 
CCBE1 (Hennekam Syndrome) (Alders et al., 2009; Connell et al., 2010) and genes associated 173 
with congenital lymphatic malformations, including FLT4 (Achen et al., 1998; Gordon et al., 2013; 174 
Joukov et al., 1996), FOXC2 (Fang et al., 2000; Sabine et al., 2012) and SOX18 (Francois et al., 175 
2008).  In all instances, with an average coverage of 10X 117.5 in all regions, we found these 176 
genes to be normal.  However, exome sequencing analysis led to the detection of a previously 177 
unreported homozygous variant in exon 9 of the CALCRL gene: NM_005795.5: c.614_616del 178 
(p.Val205del), resulting in an in-frame deletion of amino acid valine 205 within the encoded 179 
protein, referred to as CLR (Figure 1C), hereafter referred to as V205del. 180 
To date, this variant is not present in the Genome Aggregation Database (gnomAD), 181 
Exome Aggregation Consortium (ExAC), Exome Sequencing Project or the 1000 Genomes 182 
browser.  While the proband (III.4) and her unaffected daughter (IV.1) were heterozygous for the 183 
mutation, the affected fetus (IV.3) was found to be homozygous (Figure 1C). The V205del variant 184 
was confirmed by Sanger sequencing and further testing was performed in other surviving adult 185 
members of the pedigree.  Importantly, the proband’s husband (III.3), who is also a first-cousin, is 186 
heterozygous for the V205del variant (Figure 1C), thus corroborating homozygous inheritance in 187 
IV.3.  The proband’s mother, II.3, also experienced multiple pregnancy losses, and is heterozygous 188 
for the CALCRL V205del variant.  Two of the proband’s sisters (III.6 and III.10) consented to 189 
Sanger-based genetic testing and did not carry the V205del variant.  Another sister (III.12), who 190 
has also experienced significant early pregnancy losses and is married to a first cousin from the 191 
same familial pedigree (Figure 1A), declined genetic testing.        192 
Individuals III.4, II.3 and IV.1 were also heterozygous, and fetus IV.3 was homozygous, 193 
for a variant in the ASAH1 gene: c.1045C>G (p.Arg349Gly), which is present in the ExAC South 194 
Asian and European (non-Finnish) populations. Biallelic loss-of-function mutations in ASAH1 are 195 
associated with Farber lipogranulomatosis (OMIM #228000), a lysosomal storage disorder that 196 
typically manifests during infancy, or in more severe cases with perinatal lethalality or antenatal 197 
hydrops fetalis (Kattner et al., 1997).  However, we noted no clinical manifestation or symptoms 198 
indicative of this condition in IV.3 or in other family members within this four-generation 199 
pedigree.  Altogether, the family pedigree, genetic inheritance pattern and clinical phenotype 200 
support the identification of mutations in the CALCRL gene as a novel causative pathway of human 201 
NIHF. 202 
 203 
Genetic conservation of CALCRL and residue V205  204 
 The human CALCRL gene exhibits relatively few loss-of-function variants in the general 205 
population, as indicated by a high “probability of loss-of-function intolerance” (pLI) score (0.93) 206 
derived from the number of loss-of-function variants observed in the ExAC database compared to 207 
the expected number based on the size of the gene (16.9 Kb) (Lek et al., 2016).  The V205del 208 
variant itself is absent from the GnomAD database, which contains genome-scale sequence data 209 
on nearly 140,000 individuals.  In addition, this finding is highly consistent with the impaired 210 
subfertility of the heterozygous female carriers (patients II.3 and III.4), suggesting that their low 211 
fecundity would be expected to contribute fewer loss-of-function variants to the population at 212 
large. 213 
Consistently, we identified 67 conserved orthologues of the hCALCRL gene and used 214 
multiple sequence alignment (Jalview and Clustal Omega (Li et al., 2015; McWilliam et al., 2013; 215 
Sievers et al., 2011)) to establish the relative conservation of amino acid V205.  We found that 216 
V205 is fully conserved across all species, except insects, being present in 62 of the 67 species 217 
represented.  In 4 of the 5 species where the residue is not present (Lesser Hedgehog, Mouse 218 
Lemur, Sloth, and Wallaby), there is no equivalent residue.  In D. Melanogaster (~23% homology), 219 
the corresponding valine is a tyrosine. A subset of the 62 species alignment is represented in 220 
Supplemental Figure 1, and reveals stringent conservation of the V205 residue, even within a 221 
core of amino acids that displays significant sequence degeneracy amongst fishes. 222 
 223 
Molecular modeling of hCLR and hCLR(V205del)  224 
 To visualize the consequences of V205 deletion on the hCLR structure, we generated 225 
homology models of the hCLR (Figure 2A, blue) and hCLR(V205del) (Figure 2B, red) structures 226 
using SWISS-MODEL (Arnold et al., 2006; Biasini et al., 2014; Guex et al., 2009; Kiefer et al., 227 
2009), built on the structure of the corticotropin-releasing factor receptor 1 as a GPCR family B 228 
member template (Hollenstein et al., 2013).   Notably, deletion of V205 is predicted to cause loss 229 
of alpha-helical character in extracellular loop 1 and gain of an extra turn in the extracellular-230 
facing helix of transmembrane 2 (TM2, green). These changes are accompanied by predicted loss 231 
or gain of hydrogen bonding. For example, His194 loses the ability to interact with Gln215 and 232 
Thr196 undergoes a large shift in position. Asn200 and Asn201 gain and lose H-bonding contacts, 233 
respectively, and the shift of Ala206 to Ala205 contributes to the loss of alpha-helical character in 234 
ECL1. Finally, distal residues found in this area, Tyr277 and Ser284 lose the ability to interact. 235 
Importantly, previous alanine mutagenesis studies have shown that many of these affected residues 236 
are important for receptor oligomerization with RAMPs and/or ligand binding (Barwell et al., 237 
2011; Barwell et al., 2012; Watkins et al., 2016; Woolley and Conner, 2013). 238 
 Therefore, we next developed dynamic molecular modeling of wildtype hCLR (Figure 239 
2C) or hCLR(V205del) (Figure 2D) in complex with hRAMP2 (yellow), which forms a functional 240 
receptor for hAM ligand (purple), using ROSETTA and MODELLER.  The hCLR(V205del) 241 
complex reveals a shortened distance between hRAMP2 helix 2 and the hAM binding site, 242 
ultimately distorting the binding pocket and displacing the N’ terminus of hRAMP2.  Furthermore, 243 
the repositioning of hRAMP2 helix 2 causes a knock-on effect on hCLR(V205del), distorting 244 
TM1, TM6 and TM7, which are essential for presenting the receptor ligand binding pocket.  245 
Consistent with these molecular modeling predictions, Replica Exchange Monte Carlo (REMC) 246 
molecular dynamic simulations (Figure 2E and Supplemental Movie 1) confirmed a distorted 247 
hCLR(V205)-hRAMP1 and –hRAMP2 interaction, with a significantly increased root-mean-248 
square deviation (RMSD) for the hCGRP and hAM ligand docking (Figure 2F).  Collectively, 249 
these structural modeling approaches predict that the mutant hCLR(V205del) protein is likely to 250 
display ineffective binding to both hRAMPs and ligands.       251 
 252 
hCLR(V205del) abrogates cell signaling and RAMP-mediated, cell surface receptor expression 253 
 To directly test the signaling and receptor oligomerization competency of hCLR(V205del), 254 
we developed and employed several orthogonal cell-based assays.  First, using a BRET-based 255 
cAMP biosensor (Barak et al., 2008; Salahpour et al., 2012) we found that dose-dependent 256 
stimulation with the cognate peptide ligand, AM, robustly stimulated cAMP production in hCLR: 257 
hRAMP2-expressing HEK293T cells with maximal efficacy and nanomolar potency (EC50 =14.1 258 
nM), as expected based on previous studies (Hay et al., 2003; Kuwasako et al., 2011) (Figure 3A).  259 
However, the mutant hCLR(V205del) receptor exhibited a near-complete absence of cAMP 260 
production represented by the loss of both efficacy and potency (EC50 =0.019 M), and comparable 261 
in levels to mock-transfected cells (Figure 3A).  This complete loss of signaling by the 262 
hCLR(V205del) receptor implies that the V205 residue is critical for either ligand-mediated 263 
receptor activation, or for proper receptor cell surface localization, or both. 264 
Next, to distinguish between these possibilities, we adapted an Infrared Fluorogen 265 
Activating Protein (IRFAP) assay  (Fisher et al., 2014; Snyder et al., 2015; Snyder et al., 2017; 266 
Szent-Gyorgyi et al., 2008) (Supplemental Figure 2A-C) to screen for cellular co-translocation 267 
of hCLR-hRAMP heterodimer complexes to the cell surface, exploiting the fact that the forward 268 
trafficking of either hCLR or hRAMPs from the Golgi to the plasma membrane are mutually 269 
interdependent (Hay et al., 2006; McLatchie et al., 1998).  As expected, the interaction of hCLR: 270 
FAP-hRAMP2 was robustly detected at 187.5 ng and stable at all concentrations (Figure 3B, 271 
column 3). Conversely, the hCLR(V205del) variant failed to chaperone FAP-hRAMP2 to the 272 
plasma membrane, as demonstrated by a negligible to absent levels of IRFAP signal (Figure 3B, 273 
column 4), which was similar in intensity to that of pcDNA3.1 (column 1) or the non-RAMP 274 
interacting GPCR, β2-adrenergic receptor (column 2). 275 
Confocal microscopy of HEK293T cells expressing fluorescently- or epitope-tagged 276 
versions of the proteins corroborated these findings.  Briefly, cells were transfected to express 277 
3xHA-hRAMP2 protein (cyan) in the presence of Myc-hCLR or Myc-hCLR(V205del) (red) and 278 
hCLR-YFP or hCLR(V205del)-YFP (green) in order to evaluate the subcellular localization of 279 
individual oligomer complexes (Figure 3C).  In the 3xHA-RAMP2: Myc-hCLR: hCLR-YFP co-280 
transfection, cells displayed robust co-localization of all 3 wildtype proteins at the plasma 281 
membrane, as evidenced by the yellow-merged staining (top row, right column).  However, the 282 
hCLR(V205del)-YFP variant fails to traffic to the plasma membrane and remains intracellular 283 
(middle row, green).  Importantly, under this condition—which mimics the phenotypic condition 284 
of individuals who are heterozygous for the hCLR(V205del) variant—the expression of the mutant 285 
hCLR(V205del) receptor does not invoke dominant negative effects on the forward trafficking of 286 
the wildtype hRAMP2 and hCLR to the plasma membrane (middle row, right column, white 287 
merge).  Finally, none of the proteins traffic to the plasma membrane when both Myc-288 
hCLR(V205del) and hCLR(V205del)-YFP are co-expressed with 3xHA-hRAMP2 (bottom row). 289 
  290 
hCLR(V205del) fails to form oligomers with hRAMPs 291 
Since the effective signaling and plasma membrane localization of hCLR is fully dependent 292 
on RAMP protein interaction, we reasoned that the impaired functions of the hCLR(V205del) 293 
variant in the above assays might be caused principally by its inability to interact with RAMPs. To 294 
test this hypothesis, we utilized two different assays for protein-protein interaction.  First, using 295 
bioluminescence resonance energy transfer (BRET) assays, we consistently observed robust and 296 
characteristic rectangular hyperbola saturation isotherms with wildtype hCLR-rLuc and hRAMP2-297 
YFP, with a Bmax of 1.03, indicative of one site binding, and a disassociation constant of Kd=0.83 298 
(Figure 4A, top).  On the other hand, the hCLR(V205del) mutant resulted in a complete loss of 299 
BRET signal indicated by the linear, non-specific binding with a Bmax of 0.14 and a negative 300 
disassociation constant of Kd =-2.70 (Figure 4A, bottom).  Secondly, we employed in situ 301 
proximity ligation assay (PLA) (Chauhan et al., 2015), which detects protein-protein interactions 302 
at single molecule resolution within living cells.  HEK293T cells transiently co-transfected with 303 
hCLR and hRAMP2 exhibited markedly robust PLA signal (207.5 ± 24.0 signals/cell), whereas 304 
cells co-expressing the hCLR(V205del) variant showed a complete abatement of PLA signal (1.4 305 
± 0.8 signals/cell) (Figure 4B).   Collectively, these data demonstrate that V205 in hCLR is a 306 
critical residue for the formation of the hCLR:hRAMP2 heterodimer, which is furthermore 307 
required for its normal subcellular localization and signaling. 308 
 309 
Lymphatic Calcrl is essential for murine survival and lymphatic vascular development 310 
CLR is a broadly-expressed receptor with abundant expression in cardiovascular tissues 311 
and the peripheral nervous system. Similar to the family case report, global deletion of the Calcrl 312 
in mice results in mid-gestation embryonic lethality with profound interstitial edema due to 313 
arrested lymphangiogenesis—a HF phenotype that is fully recapitulated in both Adm-/- and Ramp2-314 
/- mice (Caron and Smithies, 2001; Dackor et al., 2006; Fritz-Six et al., 2008; Kechele et al., 2016). 315 
In addition, we found that placentas from Calcrl-/- fetuses also exhibited marked interstitial edema 316 
within the labyrinth and enlarged junctional zone (Figure 5A), reflecting the pathology observed 317 
in the human condition. 318 
Therefore, to gain insights into the functional consequences of lymphatic endothelial 319 
Calcrl loss during development we generated lymphatic-specific Calcrl null animals using two 320 
independent Cre-driver lines: constitutively expressed, Lyve1-Cre (Pham et al., 2010) and the 321 
inducible Prox1-CreERT2 (Srinivasan et al., 2007).  All Calcrlfl/fl;Lyve1-Cre animals died in late 322 
gestation (E16.5-E17.5) with profound interstitial edema (Figure 5B).  Similarly, tamoxifen 323 
injection of pregnant Calcrlfl/fl dams mated with Calcrlfl/fl;Prox1-CreERT2 males resulted in 324 
excision of the Calcrl gene and midgestation lethality with HF between E14.5-16.5 of 325 
Calcrlfl/fl;Prox1-CreERT2 embryos (Figure 5C, Supplementary Figure 3A-C).  Morphometric 326 
analysis of the developing jugular lymph vessels of Calcrlfl/fl;Prox1-CreERT2 embryos  revealed 327 
subcutaneous edema and significantly smaller lymphatic vessels (Figure 6A and B) that were 328 
developmentally arrested, as evidenced by a greater than 50% reduction in Ki67-positive 329 
lymphatic endothelial cells within the jugular lymph sacs (Figure 6C and D) compared to 330 
littermate Calcrlfl/fl embryos. Analysis of dermal lymphatic vessels within the embryonic skin of 331 
Calcrlfl/fl;Prox1-CreERT2 embryos also revealed the presence of developmentally arrested 332 
lymphatic capillaries that appeared significantly dilated and malformed within the environment of 333 
subcutaneous edema compared to the dermal lymphatic capillaries of normal Calcrlfl/fl embryos 334 
(Figure 6E-H). 335 
Since abnormal lymphovenous valve formation during development has recently been 336 
linked to GLD and NIHF in both mice and humans (Martin-Almedina et al., 2016), we carefully 337 
examined the lymphovenous valves of Calcrlfl/fl;Prox1-CreERT2 embryos and observed normal 338 
structural morphology, appropriate compartmentalization of blood cells from lymph and high 339 
levels of Prox1 and Lyve1 staining (Supplemental Figure 4).   Moreover, because Prox1 is 340 
expressed in myocardial cells and global loss of Calcrl results in reduced myocardial proliferation 341 
in mice (Dackor et al., 2006), we carefully evaluated the structure and development of the hearts 342 
of Calcrlfl/fl;Prox1-CreERT2 embryos and found them comparable in size and structure to wildtype 343 
littermates (Supplemental Figure 5). 344 
Collectively, these results establish that loss of functional Calcrl within the lymphatic 345 
vasculature causes a midgestational proliferative arrest in lymphangiogenesis resulting in profound 346 
HF with associated placental edema, which are phenotypes entirely consistent with the clinical 347 
presentation of NIHF in humans with the homozygous hCLR(V205del) variant. 348 
 349 
Loss of RAMP2-mediated CLR signaling in mice recapitulates the hCLR(V205del) haplotype 350 
CLR serves as the receptor for both AM and CGRP ligands, depending on which RAMP 351 
the receptor is heterodimerized with.  Thus, patients with the hCLR(V205del) variant are likely to 352 
be functionally deficient for both AM/RAMP2/3-mediated and CGRP/RAMP1-mediated 353 
signaling.  We have previously demonstrated that Ramp1 and Ramp3 null mice survive to 354 
adulthood with little to no overt phenotypes, consistent with a lack of overt phenotypes in mice 355 
deficit for CGRP (Dackor et al., 2007).  Therefore, to more carefully parse the relative 356 
contributions of RAMP2-mediated signaling, we characterized the phenotypes of a unique Ramp2 357 
transgenic line in which endothelial restoration of Ramp2 using a vascular endothelial-specific 358 
promoter to drive a Ramp2 transgene (Tg) is sufficient to partially rescue the edematous phenotype 359 
and embryonic lethality of Ramp2-/- mice (Kechele et al., 2016).  Similar to the previously reported 360 
Ramp2+/- subfertility phenotype (Kadmiel et al., 2011), Ramp2-/--Tg dams undergo implantation 361 
and maintain pregnancy to term, but they have significantly smaller litter sizes than Ramp2+/+-Tg 362 
or Ramp2+/--Tg females (Figure 7A), further supporting the observation that haploinsufficiency 363 
for CLR-RAMP2 signaling in females—both in mice and in humans—is associated with 364 
subfertility (Kadmiel et al., 2011; Li et al., 2013).  While Ramp2-/--Tg pups were born at nearly 365 
Mendelian ratios (Figure 7B), approximately 60%-70% died perinatally with marked fluid 366 
accumulation, small focal hemorrhages in the skin and HF (Figure 7C and D), likely due to the 367 
low level of VE-cadherin-mediated Ramp2 reconstitution in lymphatic vessels.  Histology 368 
confirmed substantial amounts of interstitial edema within a thickened subcutaneous layer of the 369 
skin in Ramp2-/--Tg embryos compared to littermate Ramp2+/+-Tg controls (Figure 7E).  370 
Furthermore, the placentas from edematous Ramp2-/--Tg embryos showed marked fluid-filled 371 
cavities within the labyrinth and junctional zones of the fetal placenta (Figure 7F and G).  372 
Collectively, the morphological phenotypes observed in the majority of Ramp2-/--Tg embryos, 373 
including HF, thickened skin, placental edema, and embryonic demise are fully consistent with the 374 
clinical characteristics of NIHF in humans and further establishes the CLR-RAMP2-AM signaling 375 
axis as the molecular basis for NIHF and female subfertility observed in humans with a 376 
hCLR(V205del) variant.   377 
 378 
Discussion:  379 
In summary, an in-frame deletion of a highly conserved valine reside in extracellular loop 380 
1 of the GPCR, CLR, has been identified in six members of a consanguineous family pedigree 381 
resulting in autosomal recessive GLD with NIHF in homozyogous carriers and female subfertility 382 
in heterozygous carriers.  The mutation imparts structural changes within the receptor that preclude 383 
its interaction with the requisite accessory chaperone protein RAMP, resulting in loss of receptor 384 
at the cell surface and absence of ligand-mediated signaling.  In animal models, we show that the 385 
expression of the CLR-RAMP2-AM signaling axis in lymphatic endothelial cells is both necessary 386 
and sufficient for mammalian survival and normal female reproductive function—providing a 387 
cellular and molecular foundation for the clinical manifestations observed in humans with the 388 
hCLR(V205del) variant.  The impact and relevance of these findings can be extrapolated to at least 389 
3 different areas. 390 
 First, these findings provide, to our knowledge, the third case of genetically-inherited 391 
NIHF associated with GLD, thereby increasing the repertoire of candidate factors for genetic 392 
testing and screening beyond the very recently identified disease-associated PIEZO1 and EPHB4 393 
genes.  Moreover, based on deductions from animal model studies, as well as the extensive, 4-394 
generation pedigree, we also conclude that haploinsufficiency for the CLR-RAMP2-AM axis is 395 
associated with clinical subfertility in female carriers.  Collectively, this work provides additional 396 
diagnostic criteria for causes of NIHF and female subfertility, as well as 3 additional genes for 397 
candidate genetic testing; CALCRL, ADM and RAMP2. 398 
Second, the remarkable conservation of phenotype between the human patients and the 399 
genetic animal models provides compelling evidence for the evolutionarily conserved functions of 400 
the AM-CLR-RAMP2 signaling axis in embryonic vascular development and female fertility.  In 401 
contrast, the hCLR(V205del) variant appeared to have little consequence on CGRP-mediated 402 
physiology, which is further supported by the lack of overt phenotypic effects in either CGRP-/-403 
, CGRP-/-, Ramp1-/- or Ramp3-/- mice (Dackor et al., 2007). This may help explain why antibody-404 
mediated CGRP antagonist therapies have recently shown tremendous promise, with little side-405 
effects, in several large-scale phase-III trials for the treatment of migraine (Goadsby et al., 2017; 406 
Silberstein et al., 2017).  407 
Finally, using molecular dynamic modeling and biochemical approaches we have 408 
demonstrated the requisite functions imparted by a GPCR-RAMP interaction for the normal 409 
trafficking, signaling and physiology of a family B GPCR. These findings are particularly timely, 410 
since the molecular crystallization of three family B GPCRs, CRF, GLP-1 and glucagon receptors, 411 
have recently been elucidated (Hollenstein et al., 2013; Song et al., 2017; Zhang et al., 2017).  412 
Notably, Zhang et al. demonstrated that the ECL1 region of the glucagon receptor—which also 413 
interacts with RAMPs (Weston et al., 2015)—is critical for forming the peptide binding interface.  414 
Together, these findings demonstrate that ECL1 is a functionally critical structure of Family B 415 
GPCRs, and imparts physiological relevance to this motif in humans.  Future co-crystallization of 416 
active-state family B GPCRs in oligomeric complex with RAMPs will likely reveal novel insights 417 
into the structure-function relationships imparted by these protein-protein interactions.  Indeed, 418 
while the current work was focused on the canonical RAMP-associated receptor, CLR, it is worth 419 
emphasizing that over a dozen GPCRs have been shown to interact and function through RAMPs, 420 
including calcitonin (Armour et al., 1999), parathyroid hormone  and vasointestinal peptide 421 
receptors (Christopoulos et al., 2003) as well as other non-family B GPCRs such as GPR30 422 
(Lenhart et al., 2013), glucagon (Weston et al., 2015), and calcium sensing receptors (Bouschet et 423 
al., 2005). Thus, the physiological implications of aberrant GPCR-RAMP oligomerization may be 424 
vastly underappreciated.  Furthermore, these studies open potential avenues for the development 425 
of therapeutic pharmacological chaperones to enhance GPCR-RAMP interaction as a means to 426 
promote receptor trafficking, as has successfully been accomplished for other disease-causing 427 
plasma membrane protein variants such as V2 vasopressin receptor (Morello et al., 2000), CFTR 428 
(Drumm et al., 1991), and aquaporin-2 (Tamarappoo and Verkman, 1998). 429 
 430 
Materials and Methods: 431 
Targeted capture and parallel sequencing 432 
 Genomic DNA was extracted from the fetal cord blood of family member IV.3 and from 433 
blood samples of family members II.3, III.3, III.4, III.6, III.10 and IV.1. Whole-exome sequencing 434 
was performed on exon targets isolated from patient IV.3 by capture using nextSeq Exome 435 
sequencing Platform (Illumina) at CentoGene® and an end to end bioinformatics pipeline was 436 
applied. This included base calling, primary filtering of low quality reads, and probable artifacts 437 
and annotation of variants. For medical evaluation purposes, all disease causing variants reported 438 
in HGMD®, in ClinVar (class 1 and 0) and all variants with minor allele frequencies of less than 439 
1% in the ExAC database were considered. All variants that could possibly impair the protein 440 
sequence, i.e. disruption of conserved splice sites, missense, nonsense, read-throughs or small 441 
insertion/deletion were prioritized. The percent coverage at 10x for patient IV.3 was 95.64% while 442 
the coverage for the mother III.4 and father III.3 was 96.59% and 97.10%, respectively. The 443 
average fold coverage for patient IV.3 was 117.57%, while for the mother III.4 and father III.3 444 
was 133.36% and 140.96%, respectively. 445 
 446 
Molecular Modeling of hCLR, hCLR(V205del) and RAMP-interaction 447 
 Two hCLR and hCLR(V205del) GPCR homology models were constructed. The hCLR 448 
and hCLR(V205del) sequences (UniProtKB-Q16602 and Q16602 with valine 205 deleted) were 449 
used as the targets. The GPCRs were aligned against human corticotropin-releasing factor receptor 450 
1 (PDB 4K5Y) (Hollenstein et al., 2013) using SWISS-MODEL automated mode (Biasini et al., 451 
2014). These models resulted in a Model-Template Range of 138-389 amino acids. The top 452 
homology models were chosen using the QMEAN score (Benkert et al., 2011; Benkert et al., 453 
2009a; Benkert et al., 2009b). In brief, QMEAN is a composite scoring function for the estimation 454 
of the global and local model quality. It consists of four structural descriptors: The local geometry 455 
is analyzed by a torsion angle potential over three consecutive amino acids. Two pairwise distance-456 
dependent potentials are used to assess all-atom and C-beta interactions. A solvation potential 457 
describes the burial status of the residues. Furthermore, the Corticotropin-releasing factor receptor 458 
1 was use as the target GPCR for generation of the homology model because it is a member of the 459 
secretin receptor family and the same subfamily, B1, as hCLR. Once the models were generated 460 
they were exported for use in PyMOL. In PyMOL, both GPCR structures were probed for changes 461 
in polar contacts involving side chains centered on the site of the valine 205 deletion (magenta). 462 
The labeled residues indicate the changes in predicted hydrogen bonding, large positional changes, 463 
cysteine bonds, or the site of the amino acid deletion. 464 
 Homology models of hCLR were generated using the recently published cryo-EM structure 465 
of 5VAI and the X-ray crystallographic of 3N7P as described previously (Woolley et al., 2017). 466 
The position of the N terminal region of hRAMP1 was aided by superimposing the crystal structure 467 
of 4RWG to the homology model of hCLR. After which the hCLR component (leaving the RAMP 468 
region intact) was removed and the complex minimized using MODELLER. The transmembrane 469 
component of hRAMP1 was generated using an in house script and docked into the hCLR + N’ 470 
terminal hRAMP model using GRAMM in Low resolution helix docking mode. Each of the 10000 471 
docked positions of hRAMP1 TM against the hCLR-RAMP1 N’ terminal model was refined using 472 
ROSETTA. The top 1% of the best scoring structures were clustered using a cutoff of 2A. 3 473 
clusters emerged and the middle structure of each cluster was used to generate 3 complete 474 
homology models of the hCLR-hRAMP1 complex. Replica Exchange Monte Carlo (REMC) 475 
simulations were used refine each model (16 temperatures spanning 300K-500K following a 476 
Boltzmann distribution) after which the final structures were scored using ROSETTA and the best 477 
structure was used for the subsequent study. The deletion of V205 was performed using 478 
MODELLER.  Parallel REMC simulations of the WT hCLR-hRAMP1 complex as well as the 479 
deletion were performed and compared. 480 
 481 
Generation of Human Calcitonin Receptor-Like Receptor (hCLR) and hRAMP2 Expression 482 
Constructs 483 
The hCLR mammalian expression plasmid Myc-hCLR-phRLucN3 (hCLR-rLuc) were 484 
generously donated by the laboratory of Dr. Michel Bouvier, Université de Montréal and used as 485 
the template for site-directed mutagenesis using the QuikChange II XL Site-Directed Mutagenesis 486 
Kit (Agilent Genomics) to generate the hCLR(V205del) mutant. Mutagenesis primers were 487 
designed using QuikChange Primer Design Tool (Agilent Genomics). Myc-hCLR and Myc-488 
hCLR(V205del) were further subcloned into pcDNA3.1(+) to remove the rLuc moiety for 489 
additional experiments. The hRAMP2 mammalian expression plasmid hRAMP2/pcDNA3.1 was 490 
purchased from the cDNA Resource Center (Bloomsburg University). The hRAMP2 gene was 491 
subcloned into the pEYFP-N1 vector to generate hRAMP2-eYFP. All constructs were verified by 492 
DNA sequencing.  493 
 494 
Bioluminescence Resonance Energy Transfer (BRET)  495 
HEK293T cells were maintained in standard conditions. Transfections were carried out 496 
using Lipofectamine 2000 Reagent (Thermo Fisher) following the manufacturer’s specifications. 497 
In brief, 96-well white, clear bottom plates (Corning) were coated with poly-D-lysine. Fifty-498 
thousand cells were seeded into each well and grown overnight in 37OC, 5% CO2. The next day, 499 
cells were transfected with a serial dilution of hRAMP2-eYFP DNA (15µg to 0µg) with a constant 500 
concentration of hCLR-rLuc or hCLR(V205del) to generate the saturation isotherm. On day three, 501 
the media was aspirated and replaced with 90µL 1xPBS and 10µL of 10x coelenterazine, incubated 502 
for 10 mins, and the plates were read on a Mithras LB 940 Multimode Microplate Reader (Berthold 503 
Technologies).  504 
 505 
cAMP EPAC Biosensor Assay 506 
HEK293T cells were transfected using the calcium phosphate transfection protocol, see 507 
reference above. In brief, 10cm dishes were seeded with 4 million cells and grown overnight in 508 
standard conditions. The next day, each dish was transfected with 4µg EPAC biosensor, 2.5µg of 509 
hRAMP2, and 2.5µg of either hCLR or hCLR(V205) or empty vector. After 18 hours, cells are 510 
harvest and seeded at 100,000 cells per well into a white 96-well poly-D-lysine coated plate in 511 
phenol-free reduced serum DMEM (supplemented with 2% FBS, 1% HEPES, and 750µL of 512 
Gentamicin (Sigma)). On the day of the experiment, fresh AM stock was made at 1mM and a half-513 
log dilution series was generated with a final concentration in the assay of 10µM to 31.6pM. Media 514 
was aspirated from each well and replace with 80µL of PBS and 10µL of 10x coelenterazine and 515 
incubated 10 mins. Next, 10µL of AM was added to each well and the plate was incubated for 45 516 
mins in the dark at room temperature. All assays were read on a Mithras LB 940 Multimode 517 
Microplate Reader.  518 
 519 
Fluorogen Activating Protein (FAP) Assay 520 
Fluorogen was obtained from the laboratory of Dr. Alan Waggoner, Carnegie Mellon 521 
University Technology Center of Networks and Pathways, Pittsburgh. Gateway cloning 522 
technology (Thermo Fisher) was use to generate the FAP-RAMP2 fusion protein. To investigate 523 
the hRAMP2 chaperone activity all experiments were carried out using poly-D-lysine coated, 24-524 
well clear plates. One hundred and seventy five thousand HEK293T cells were seeded into each 525 
well and grown overnight. The following day, each well was transfected by calcium phosphate 526 
transfection with 250ng of hRAMP2 and a serial dilution of hCLR, hCLR(V205del), or pcDNA3.1 527 
(1.5µg to 11.7ng). Cells were grown for 18 hours in transfection media and assayed for FAP 528 
expression. Media was aspirated and replaced with 250µL of room temperature PBS with a 1:6000 529 
dilution of fluorogen SCi1 and incubated for 10 mins. Next, 250µL of PBS without fluorogen and 530 
each plate was read on an Odyssey CLx imaging system (Li-COR Biosciences).  531 
 532 
Proximity Ligation Assay 533 
HEK293T cells were seeded into poly-D-lysine coated MatTek plates and transfected with 534 
hCLR or hCLR(V205) or hβ2 Adrenergic receptor and hRAMP2 or pcDNA3.1 using calcium 535 
phosphate. At 24 hours post-transfection cells were washed with room temperature PBS and fixed 536 
onto plates with fresh 4% paraformaldehyde in PBS. Cells were then probed by proximity ligation 537 
assay (PLA) using the Duolink In Situ Red Kit Goat/Rabbit (Sigma) in a humidity chamber 538 
according to manufacturer’s specifications. Briefly, cells were blocked with 4% BSA in PBS, 539 
incubated with appropriate primary antibodies and then incubated with PLA probes, anti-Goat and 540 
anti-Rabbit secondary antibodies conjugated to unique oligonucleotides. Each sample was treated 541 
with a ligation solution which allows the oligo pairs in close proximity for form a close loop. Next, 542 
rolling-circle amplification was initiated by the addition of an amplification solution that contains 543 
polymerase and fluorescently labeled oligonucleotides which produces discrete fluorescent dots. 544 
After the PLA protocol, cells were counterstained with a mouse anti-β-catenin primary antibody 545 
(BD Biosciences, 610153) and donkey anti-mouse Alexa488 secondary antibody to visualize the 546 
plasma membrane and Hoeschet to mark the nucleus. Cells were analyzed by confocal laser 547 
scanning microscopy. A minimum of 25 cells were imaged for analysis and each red dot was 548 
scored as a single interaction using BlobFinder software (Allalou and Wahlby, 2009).  549 
 550 
Animal Studies 551 
All animal procedures were approved by the University of North Carolina Chapel Hill’s 552 
Institutional Animal Care and Use Committee.  553 
Calcrlfl/fl/Prox1-CreERT2 mice were generated by crossing Calcrlfl/fl mice (1) that were on 554 
a N7-10 on C57BL/6 background to Prox1-CreERT2 NMRI line (Srinivasan et al., 2007) a kind gift 555 
from Dr. Guillermo Oliver, Northwestern University. Cre-mediated recombination was induced 556 
by administering tamoxifen (Tam) (Sigma Aldrich T5648) dissolved in corn oil and ethanol to 557 
pregnant female mice aged 4-6 months for 3 consecutive days from E8.5 to E10.5 at a dose of 5 558 
mg/40 g intraperitoneally and their embryos harvested at various stages during gestation. 559 
Calcrlfl/fl/Lyve1-Cre mice was generated by crossing the aforementioned Calcrlfl/fl line to Lyve-1 560 
Cre+ line obtained from Jackson Lab (JAX stock #012601) (Pham et al., 2010). Ramp2+/- were 561 
crossed to Tg(Cdh5-Ramp2)1Car hemizygous mice and maintained on an isogenic C57BL/6 562 
background as previously reported (Dackor et al., 2007; Kechele et al., 2016).  Ramp2+/- males 563 
were crossed to Ramp2+/-; Tg(Cdh5-Ramp2) dames and viable progeny were harvested during late 564 
gestation. Primers used for genotyping were: Calcrl wildtype allele, 5’-565 
GCGGAGCATATTCAATCACAAG-3’ and 5’-GAAATGTGCTGTATGTTCAAGC-3’; Calcrl 566 
floxed allele, 5’GCGGAGCATATTCAATCACAAG-3’ and 5’-567 
GACGAGTTCTTCTGAGGGGA-3’; Prox1-CreERT2 allele, 5’-568 
CGAGCTCTTTCTCTCTACAGTTCAACA-3’  and  5’-569 
GGCCAGTAACGTTAGGGAGAGG-3’; Lyve-1 Cre+ allele, 5’-570 
TGCCACCTGAAGTCTCTCCT-3’  and 5’-TGAGCCACAGAAGGGTTAGG-3’ and 5’-571 
GAGGATGGGGACTGAAACTG-3’; excised Calcrl allele, 572 
5’GCGGAGCATATTCAATCACAAG-3’ and 5’-GAATAAGTTGAGCTGGGCAG-3’; Ramp2 573 
wildtype allele, 5’-FAAGTCAGGCAGTCAGGGTTG-3’ and 5’-574 
TCTGTCTGGATGCTGCCTTGC-3’; Ramp2 null allele, 5’-GACGAGTTCTTCTGAGGGGA-3’ 575 
and 5’-TCTGTCTGGATGCTGCCTTGC-3’; and the Tg(Cdh5-Ramp2) allele, 5’-576 
GACTACAAAGACGATGACGACAAGC-3’ and 5’-577 
GTCCATGCAACTCTTGTACTCATACC-3’.   578 
 579 
Tissue Preparation, Histology, and Immunofluorescence 580 
For cellular staining, 500,000 HEK293T cells were seeded into 35 mm MatTek glass 581 
bottom dishes coated with poly-D-lysine and grown over-night. Cells were transfected with 150ng 582 
of hRAMP2 and 150ng of either hCLR or hCLR(V205del) or pcDNA3.1 using calcium phosphate. 583 
The following day, cells were washed with room temperature PBS and fixed onto plates with fresh 584 
4% paraformaldehyde in PBS.  585 
Viable mouse embryos were collected and fixed in 4% paraformaldehyde in PBS for 24 586 
hours at 4°C. Whole mount back skin was collected and stained as described in Li et al. (Li and 587 
Mukouyama, 2011).  Briefly, limb skins were peeled after dehydrating in 100% MeOH followed 588 
by rehydration and antibody staining. Embryos were paraffin embedded, transversely sectioned, 589 
and stained with either hematoxylin and eosin or Masson’s Trichrome according to standard 590 
protocols. Tissues and cells were washed with PBS and permeabilized with 0.1% Triton X-100 in 591 
PBS, washed, and blocked for 1 hour at room temperature with 5% normal donkey serum or 4% 592 
BSA in PBS. Samples were probed with primary antibodies directed towards rabbit anti-LYVE1 593 
(1:250, Fitzgerald), rat anti-Ki67 (1:150, Vector Labs VP-RM04), rabbit anti-pHH3 (1:200, Cell 594 
Signaling 6-570) human anti-Prox1 (1:100, R&D Systems AF2727), Syrian hamster-anti-595 
podoplanin (1:100, DSHB8.1.1), rat anti-PECAM (1:100, BD Pharmingen 550274), rabbit anti-596 
myc (1:500, Abcam ab9106) and goat anti-HA (1:250, Abcam ab9134) overnight at 4°C. Samples 597 
were washed with 0.1% Triton X-100 in PBS and probed with donkey anti-rabbit Cy2 (1:200, 598 
Jackson ImmunoResearch) and donkey anti-goat Cy3 (1:400, Jackson ImmunoResearch) 599 
conjugated secondary antibodies for 1.5 hours at room temperature in the dark. Bisbenzimide H 600 
33258 (Hoechst) (1:1000, Sigma B1155) was used to label nuclei. Samples were washed with PBS 601 
and imaged.  602 
 603 
Microscopy and Image Analysis 604 
Fixed whole mount mouse embryos were imaged using a MZ16FA dissecting stereoscope 605 
(Leica) with a QImaging Micropublisher 5.0 color camera using QCapture imaging software 606 
(QImaging).  H&E and Masson’s Trichrome stained tissues were imaged using on a Dialux 20 607 
microscope (Leitz) using similar camera and software. Fluorescently stained mouse tissue was 608 
imaged using either a Nikon E800 fluorescence microscope with a Hamamatsu Orca camera and 609 
MetaMorph software (Molecular Devices Corporation) or a Zeiss LSM 700 Confocal Laser 610 
scanning microscope and ZEN 2011 software. Stained HEK293T cells were visualized with a 611 
Zeiss 880 scanning confocal microscope mounted on an Inverted Axio Observer Z1 equipped with 612 
Definite Focus. All images were psuedocolored and analyzed using ImageJ (NIH), Fiji and R-613 
values were calculated using Coloc2 (Schindelin et al., 2012). 614 
 615 
Real-Time qPCR 616 
Mouse embryonic tissue was collected and stored in RNAlater (Ambion AM7021). RNA 617 
was extracted and converted to cDNA as per Davis et al. (Davis et al., 2017). HEK293T cells were 618 
seeded at 2.5 million cells per 10cm dish and grown over-night in standard conditions (DMEM 619 
supplemented with 10% FBS, 1% HEPES, and 750µL of Gentamicin (Sigma)). Transfections were 620 
carried out using calcium phosphate transfection as outlined by Kingston R.E. et al (Kingston et 621 
al., 2003a; Kingston et al., 2003b). Briefly, one milliliter of transfection mixture containing 10µg 622 
of Myc-hCLR, Myc-hCLR(V205del), or pcDNA3.1 was added to each dish and grown over-night. 623 
RNA from tissues and cells was harvested using TRIzol reagent (Ambion 15596026) followed by 624 
DNase (Promega M6101) treatment and cDNA prepared using iScript (BioRad 170-8890).  625 
Quantitative RT-PCR was performed using single-tube Assay on Demand (Thermo Fisher 626 
Scientific/Applied Biosystems) for human CALCRL (Hs00907738_m1), mouse Calcrl 627 
(Mm00516986_m1), human GAPDH (4310884E), and mouse Gapdh (Mm99999915_g1) on a 628 
StepOnePlus Real-Time PCR system (Applied Biosystems). Comparative CT method was used 629 
to analyze relative gene expression normalized to GAPDH housekeeping control.   630 
 631 
Statistical Analysis 632 
Statistical analysis was determined using GraphPad 5.0 and the data is represented as the mean ± 633 
S.E.M.  Significant differences were determined by oneway ANOVA with Tukey’s Multiple 634 
Comparison test and represented as *p < 0.05, **p < 0.01, and ***p<0.001. 635 
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 911 
Figure 1. Familial pedigree, placental histology and sequencing traces of family with NIHF. (A) Whole 912 
exome sequencing identified mutations in subject IV.3 in hCALCRL following the elimination of all previously 913 
implicated candidate genes. Parents, III.3 and III.4 and maternal grandmother, were confirmed as 914 
heterozygous carriers of the hCALCRL(V205del) variant. Family history gives rise to two phenotypes 915 
dependent upon haplotype; subfertility and non-immune hydrops fetalis. (B) Placental histology from 916 
affected homozygous fetuses (IV.2 and IV.3) compared to a gestational-matched, normal placenta. The 917 
right column represents enlargements of boxed areas in the left column.  Arrow heads indicate fetal vessels. 918 
In the case of the normal placenta, these vessels are completely filled with fetal erythrocytes and distributed 919 
both at the periphery and closer to the central villus core. In the case of the two affected placentas, the fetal 920 
vessels are more commonly found near the villus periphery, are compressed, and contain fewer 921 
erythrocytes. Arrows indicate presence of scattered Hofbaeur cells. Asterisks indicate regions of severe 922 
edema within the chorionic villi of the affected placentas—a finding not seen in the normal placenta. (C) 923 
Whole exome sequencing traces for IV.3, III.4, and III.3 showing the amino acid residue valine 205 deletion 924 
(yellow). In individuals III.4 and III.3, the heterozygous allele (gray) is represented by the double peak. 925 
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 928 
 929 
 930 
Figure 2. Predicted structural changes and molecular dynamic modeling of wildtype and mutant 931 
hCLR and hCLR:RAMP2 complexes. (A/B) Predicted structural conformations of the hCLR and 932 
hCLR(V205del) by homology modeling using Swiss-Model. Cartoon views of the receptors predict structural 933 
changes centered on the site of mutation in extra cellular loop 1 (green). Inset shows predicted interactions 934 
involving side-chains and key residues are labeled to highlight changes in hydrogen bonding (H194/194, 935 
N200/200, N201/201, Q216/215, Y278/277, and S285/284), large residue positional changes (T196), and 936 
the site of deletion (V205 and A205). (C/D) Snap-shots of CLR/RAMP2/AM complexes after replica Monte 937 
Carlo simulations with either wild-type (C) or V205del (D) CLR. (E) Overlay of the RAMP/ECL1 interface of 938 
WT CLR/RAMP2/AM (blue) and CLR(V205del)/RAMP2/AM (red) complexes after replica exchange Monte 939 
Carlo simulations. (F) Changes in root-mean-squared-deviation of WT and V205del CLR in complex with 940 
both RAMP1 and CGRP or RAMP2 and AM during replica exchange Monte Carlo simulations. 941 
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Figure 3. 943 
 944 
 945 
 946 
 947 
 948 
Figure 3. hCLR (V205del) exhibits impaired signaling and plasma membrane localization. (A) 949 
Detection of cAMP production with the EPAC biosensor after 45 minutes of adrenomedullin (AM) stimulation 950 
of hCLR:hRAMP2 or hCLR(V205del):hRAMP2. (B) Infrared 24-well plate imaging of transiently transfected 951 
HEK293T cells with MarsCy1(FAP)-tagged hRAMP2. Increasing amounts of pcDNA3.1, hβ2ADR, hCLR, 952 
and hCLR (V205del) were co-transfected and cells were stained with the MarsCy1 and membrane 953 
impermeant fluorogen SCi1.  Compare cell surface expression to the pcDNA negative control. SCi1 stained 954 
cells were scanned at 700nm (red, SCi1). (C) Confocal microscopy of HEK293T cells expressing HA-955 
hRAMP2 (cyan), Myc-hCLR (red) and hCLR-YFP (green). The top row shows the colocalization of all 3 956 
wildtype proteins at the plasma membrane resulting in yellow-cyan color. The middle row shows the 957 
changes in protein distribution with co-expression of hCLR (V205)-YFP protein: only wildtype HA-RAMP2 958 
and Myc-hCLR colocalize to the plasma membrane (white merge), while the distribution of the hCLR 959 
(V205)-YFP protein (green) remains intracellular. The bottom row shows complete absence of all 3 proteins 960 
at the plasma membrane when both mutant forms of the hCLR(V205) receptor are expressed. Far right 961 
column shows the boxed regions at higher magnification. Scale bar 10 μm. 962 
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 966 
 967 
 968 
Figure 4. hCLR(V205del) does not interact with RAMPs. (A) Representative saturation isotherms from 969 
BRET assays of transiently transfected HEK293T cells with hCLR (top graph) or hCLR(V205) (bottom 970 
graph) (fused to renilla luciferase) and increasing amounts of hRAMP2 (fused to eYFP).  Experiments were 971 
performed at least 3 times and a representative experiment is shown. (B) Proximity Ligation Assay in 972 
transiently transfected HEK293T cells. Red indicates positive PLA signal, blue is nuclear DAPI stain, green 973 
is plasma membrane β-catenin. Negative controls included no transfection of hRAMP2.  Graph depicts 974 
quantitation of signal, with asterisks denoting significant differences compared to control, P < 0.001. Scale 975 
bar 10 μm. 976 
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 980 
Figure 5. Placental edema, hydrops fetalis and fetal demise in mice lacking Calcrl. (A) Placenta from 981 
E13.5 Calcrl+/+ and edematous Calcrl-/- littermates, revealing significant interstitial edema within an 982 
expanded junctional zone (jz). Yellow arrows highlight fluid filled spaces in the jz. (B) Representative images 983 
of E17.5 Calcrlfl/fl and Calcrlfl/fl/Lyve1-Cre littermates. Asterisks indicate edema. n = 5-7 animals in each 984 
group. Scale Bars, 2 mm (C) Representative images of E14.5 Calcrlfl/fl and Calcrlfl/fl;Prox1-CreERT2 985 
littermates from tamoxifen treated dams. Asterisks indicate edema. n = 8-10 animals in each group. Scale 986 
Bars, 2 mm.  987 
Figure 6. 988 
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 990 
 991 
Figure 6. Lymphatic deletion of Calcrl leads to developmentally-arrested lymphatics, hypoplastic 992 
jugular lymph sacs and dilated dermal lymphatic vessels. (A) Measurement of jugular lymph sac area 993 
in E14.5 Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 embryos. Quantitative data are represented as mean and 994 
SEM for area. n = 6-7 animals per group. (B) Representative images of H&E stained sections of E14.5 995 
Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 embryos showing jugular lymph sac (JLS), jugular vein (JV) and 996 
severe edema (*). (C) Number of Ki67-positive cells per jugular lymph sac in Calcrlfl/fl and Calcrlfl/fl/Prox1-997 
CreERT2 embryos. Quantitative data are represented as mean and SEM for number of Ki67-positive cells. 998 
n = 6 animals per group. (D) Representative images of LYVE1 (green), PROX1 (red), and Ki67 (blue) 999 
stained sections of E14.5 Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 embryos showing proliferating cells in jugular 1000 
lymph sac (JLS). Boxed regions are shown as magnified insets. Arrowheads highlight Ki67 positive 1001 
lymphatic endothelial cells. Scale Bars, 100 µm. (E) Dermal lymphatic vessel diameter of Calcrlfl/fl and 1002 
Calcrlfl/fl/Prox1-CreERT2 embryos. n = 3-5 animals per group. (F) Podoplanin (PDPN, red) stained dermal 1003 
lymphatic vessels from E13.5 Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 embryos. White line highlights width of 1004 
the lymphatic vessel. Scale Bars, 25 µm. (G) Quantification of phosphohistone H3 (pHH3) positive cells in 1005 
E13.5 Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 dermal lymphatic vessels. Data are represented as mean and 1006 
SEM for number of pHH3-positive cells per branch. n = 3-5 animals per group. (H) Representative images 1007 
of PDPN (red) and pHH3 (green) stained dermal lymphatics of E13.5 Calcrlfl/fl and Calcrlfl/fl/Prox1-CreERT2 1008 
embryos. Arrowheads indicate pHH3-positive cells.  Quantitative data are represented as mean and SEM.  1009 
In all panels, significance was determined by Student t test (tail=2, type=2) with *p<0.05, **p<0.005, 1010 
***p<0.0001.  1011 
Figure 7. 1012 
 1013 
 1014 
Figure 7. Genetic loss of Ramp2 leads to subfertility, perinatal hydrops fetalis, and lethality.  (A) 1015 
Litter sizes from Ramp2+/- ntg males crossed with Ramp2+/+Tg, Ramp2+/-Tg, and Ramp2-/-Tg females. n = 1016 
8-12 litters per genotype.  Significance was determined by one-way ANOVA with Tukey’s Multiple 1017 
Comparison test. (B) Breeding results, both expected and observed Mendelian ratios from Ramp2+/- ntg 1018 
male crossed to Ramp2-/-Tg female. N = 38 from 7 litters.  Representative images of (C) P1 and (D) E18.5 1019 
Ramp2-/-Tg mice compared to littermate controls. Representative histological images of (E) skin and (F) 1020 
placenta from E18.5 Ramp2+/+Tg and edematous Ramp2-/-Tg littermates. Double-sided arrow indicates 1021 
subcutaneous edema. (G) Higher magnification of boxed regions from panel F. Yellow arrow points to fluid 1022 
filled edematous regions. Small arrowheads indicate abnormally shaped trophoblast cells lining the 1023 
chorionic plate. lb: labyrinth, cp: chorionic plate. Scale bars:  5 mm (C-D) and 500 μm (E-F). 1024 
